Bath & Body Works (NYSE:BBWI) Shares Up 8.9% – Time to Buy?

Bath & Body Works, Inc. (NYSE:BBWI) shares traded up 8.9% during trading on Monday . The stock traded as high as $18.39 and last traded at $18.2940. 1,709,397 shares were traded during trading, a decline of 67% from the average session volume of 5,247,519 shares. The stock had previously closed at $16.80.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on BBWI shares. Zacks Research raised Bath & Body Works from a “strong sell” rating to a “hold” rating in a research report on Tuesday, January 20th. Robert W. Baird set a $20.00 target price on Bath & Body Works in a report on Wednesday, December 17th. Telsey Advisory Group boosted their price target on Bath & Body Works from $23.00 to $25.00 and gave the company a “market perform” rating in a research note on Thursday, March 5th. Jefferies Financial Group assumed coverage on shares of Bath & Body Works in a report on Wednesday, January 14th. They issued a “hold” rating and a $24.00 target price on the stock. Finally, Deutsche Bank Aktiengesellschaft upped their price target on shares of Bath & Body Works from $21.00 to $22.00 and gave the stock a “hold” rating in a report on Tuesday, March 3rd. Three analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $24.00.

Bath & Body Works Price Performance

The business’s fifty day moving average price is $21.50 and its 200 day moving average price is $22.18. The stock has a market cap of $3.83 billion, a P/E ratio of 5.94, a PEG ratio of 1.87 and a beta of 1.48.

Bath & Body Works (NYSE:BBWI) last announced its quarterly earnings results on Wednesday, March 4th. The company reported $2.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.28. The company had revenue of $2.72 billion for the quarter, compared to analyst estimates of $2.59 billion. Bath & Body Works had a net margin of 8.90% and a negative return on equity of 45.60%. The firm’s revenue was down 2.3% on a year-over-year basis. During the same period in the previous year, the firm posted $2.09 EPS. Bath & Body Works has set its Q1 2026 guidance at 0.240-0.300 EPS and its FY 2026 guidance at 2.400-2.650 EPS. On average, analysts predict that Bath & Body Works, Inc. will post 3.3 earnings per share for the current fiscal year.

Bath & Body Works Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 6th. Investors of record on Friday, February 20th were issued a dividend of $0.20 per share. The ex-dividend date of this dividend was Friday, February 20th. This represents a $0.80 annualized dividend and a dividend yield of 4.2%. Bath & Body Works’s dividend payout ratio (DPR) is 25.40%.

Institutional Trading of Bath & Body Works

A number of hedge funds have recently made changes to their positions in BBWI. Royal Bank of Canada raised its holdings in Bath & Body Works by 92.8% in the 1st quarter. Royal Bank of Canada now owns 59,877 shares of the company’s stock valued at $1,815,000 after buying an additional 28,815 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Bath & Body Works by 15.7% during the first quarter. Goldman Sachs Group Inc. now owns 645,970 shares of the company’s stock valued at $19,586,000 after acquiring an additional 87,529 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Bath & Body Works by 7.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 562,757 shares of the company’s stock worth $17,063,000 after purchasing an additional 36,684 shares during the last quarter. Intech Investment Management LLC acquired a new stake in Bath & Body Works in the first quarter valued at $1,155,000. Finally, Geneos Wealth Management Inc. raised its position in Bath & Body Works by 217.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 1,169 shares of the company’s stock worth $35,000 after purchasing an additional 801 shares during the last quarter. 95.14% of the stock is owned by institutional investors and hedge funds.

Bath & Body Works Company Profile

Bath & Body Works, Inc is a leading specialty retailer focused on personal care, home fragrance and complementary products. Through its flagship Bath & Body Works brand, the company offers a diverse assortment of shower gels, lotions, fragrance mists, candles and home fragrance items. Its product portfolio also includes the White Barn Candle Co range of premium scented candles and diffusers. Bath & Body Works serves consumers through a combination of brick-and-mortar stores and e-commerce platforms, delivering seasonal collections, limited-edition releases and signature scent lines.

Founded in 1990 as part of Limited Brands (now L Brands), Bath & Body Works opened its first store in New Albany, Ohio, and quickly expanded across the United States.